Εξώφυλλο

The effect of sodium glucose Co-transport 2 inhibitors on cognitive impairment and depression in type 2 diabetes mellitus patients

Background and aim: Type 2 diabetes mellitus (T2DM) is a prevalent metabolic disorder often associated with thyroid dysfunction. Sodium-glucose co-transport 2 (SGLT2) inhibitors, a novel class of medications for T2DM, have shown potential effects on various physiological systems, including the centr...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Ashurova Nodirahon (Συγγραφέας), Haya Majid (Συγγραφέας), Swati Waghdhare (Συγγραφέας), Divya Vohora (Συγγραφέας), Nidhi (Συγγραφέας)
Μορφή:	Βιβλίο
Έκδοση:	Elsevier, 2024-03-01T00:00:00Z.
Θέματα:	article
Διαθέσιμο Online:	Connect to this object online.
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια

Influence of sodium glucose co-transporter 2 inhibitors on fatty liver index parameters in type 2 diabetes mellitus
από: Mohammed Ali Gameil, κ.ά.
Έκδοση: (2020)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
από: Nunzia D'Onofrio, κ.ά.
Έκδοση: (2021)

Sodium-glucose co-transporter 2 inhibitors - a review article
από: Marcin Makuch, κ.ά.
Έκδοση: (2019)

Sodium-glucose co-transporter 2 inhibitors - a review article
από: Marcin Makuch, κ.ά.
Έκδοση: (2019)

Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
από: Yuling Jing, κ.ά.
Έκδοση: (2022)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
από: Daniel H. Van Raalte, κ.ά.
Έκδοση: (2022)

Sodium glucose co-transporter 2 inhibitors in heart failure therapy
από: Yüksel Çavuşoğlu, κ.ά.
Έκδοση: (2020)

Current developments in peritoneal glucose transport and sodium-glucose co-transporter 2 inhibitors during peritoneal dialysis
από: Fan Yang, κ.ά.
Έκδοση: (2023)

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
από: Yangli Ye, κ.ά.
Έκδοση: (2019)

Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
από: Stephen Melnick, κ.ά.
Έκδοση: (2018)

A model‐based meta analysis study of sodium glucose co‐transporter‐2 inhibitors
από: Xueting Yao, κ.ά.
Έκδοση: (2023)

Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
από: Anthony T. P. Chan, κ.ά.
Έκδοση: (2022)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
από: Joshua J Neumiller
Έκδοση: (2014)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents
από: Eva M Vivian
Έκδοση: (2014)

Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: A system review and network meta-analysis
από: Lei Tian, κ.ά.
Έκδοση: (2022)

Metabolic reprogramming as the basis for sodium-glucose co-transporter type 2 inhibitors cardio- and nephroprotective effect
από: O N. Kurochkina, κ.ά.
Έκδοση: (2024)

Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews
από: Ryan Pelletier, κ.ά.
Έκδοση: (2021)

The clinical cases of ketoacidosis in patients with 2 type diabetes treated with inhibitors of sodium-glucose co-transporter
από: Diana Sh. Avzaletdinova, κ.ά.
Έκδοση: (2021)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
από: Jun Tang, κ.ά.
Έκδοση: (2022)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
από: Chun Xing Li, κ.ά.
Έκδοση: (2023)

The analysis of a wide spectrum of activity of Sodium-Glucose co-transporter-2 inhibitors. A literature review
από: Magdalena Kozioł, κ.ά.
Έκδοση: (2020)

Polypharmacology of clinical sodium glucose co‐transport protein 2 inhibitors and relationship to suspected adverse drug reactions
από: Karan Matharu, κ.ά.
Έκδοση: (2021)

Sodium-glucose co-transporter-2 inhibitors - empagliflozin and dapagliflozin as future therapy for Alport Syndrome, literature review
από: Magdalena Kłusek, κ.ά.
Έκδοση: (2024)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
από: T. M. Bukatina, κ.ά.
Έκδοση: (2018)

Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus
από: Tetsuo Hayakawa, κ.ά.
Έκδοση: (2022)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
από: Sarah L. Armour, κ.ά.
Έκδοση: (2022)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
από: Hui Zhao, κ.ά.
Έκδοση: (2023)

A review on the medicinal chemistry of sodium glucose co-transporter 2 inhibitors (SGLT2-I): Update from 2010 to present
από: Jonali Ramani, κ.ά.
Έκδοση: (2022)

Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Hemoglobin Levels: A Meta-analysis of Randomized Controlled Trials
από: Wei Qu, κ.ά.
Έκδοση: (2021)

A New Chapter in the Treatment of Patients with Heart Failure. The Role of Sodium-Glucose Co-transporter Type 2 Inhibitors
από: D. P. Golubovskaya, κ.ά.
Έκδοση: (2022)

Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans
από: Min-Soo Kim, κ.ά.
Έκδοση: (2023)

Preclinical Studies of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, and Donepezil Combined Therapy in Alzheimer's Disease
από: Gabriela Dumitrita Stanciu, κ.ά.
Έκδοση: (2023)

Dual-Target Compounds against Type 2 <i>Diabetes Mellitus</i>: Proof of Concept for Sodium Dependent Glucose Transporter (SGLT) and Glycogen Phosphorylase (GP) Inhibitors
από: Ádám Sipos, κ.ά.
Έκδοση: (2021)

Bibliometric and visualized analysis of sodium-Glucose cotransporter 2 inhibitors
από: He Sun, κ.ά.
Έκδοση: (2023)

The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes
από: Masahiko Iwamoto, κ.ά.
Έκδοση: (2022)

The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis
από: Mahmoud Kandeel, κ.ά.
Έκδοση: (2022)

In vitro characterization of luseogliflozin, a potent and competitive sodium glucose co-transporter 2 inhibitor: Inhibition kinetics and binding studies
από: Saeko Uchida, κ.ά.
Έκδοση: (2015)

Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease
από: Rabab Mahmoud Ahmed, κ.ά.
Έκδοση: (2024)

Genito-urinary infection risk estimates during sodium glucose co-transporter 2 inhibitor exposure in everyday clinical practice.
από: Beata Jacuś, κ.ά.
Έκδοση: (2021)

Type 2 Diabetes Mellitus and Cognitive Impairment
από: Johanda Damanik, κ.ά.
Έκδοση: (2021)